| Primary |
| Rheumatoid Arthritis |
60.0% |
| Abortion Induced |
8.0% |
| Juvenile Idiopathic Arthritis |
8.0% |
| Arthritis |
4.0% |
| B Precursor Type Acute Leukaemia |
4.0% |
| B-cell Lymphoma |
4.0% |
| Diffuse Large B-cell Lymphoma |
4.0% |
| Polyarthritis |
4.0% |
| Sedative Therapy |
4.0% |
|
| Anaemia |
6.7% |
| Bronchial Carcinoma |
6.7% |
| Hepatitis B |
6.7% |
| Hypersensitivity |
6.7% |
| Mucosal Inflammation |
6.7% |
| Mycobacterial Infection |
6.7% |
| Nasal Congestion |
6.7% |
| Necrotising Fasciitis |
6.7% |
| Nephropathy Toxic |
6.7% |
| Pneumonia |
6.7% |
| Staphylococcal Sepsis |
6.7% |
| Syndactyly |
6.7% |
| Tonsil Cancer |
6.7% |
| Toxicity To Various Agents |
6.7% |
| Vomiting |
6.7% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
20.4% |
| Product Used For Unknown Indication |
12.7% |
| Rheumatoid Arthritis |
9.4% |
| Primitive Neuroectodermal Tumour |
6.6% |
| Burkitt's Lymphoma |
5.5% |
| Malignant Lymphoid Neoplasm |
5.5% |
| Lymphoblastic Lymphoma |
4.4% |
| Aesthesioneuroblastoma |
3.9% |
| Bone Sarcoma |
3.9% |
| Diffuse Large B-cell Lymphoma |
3.3% |
| Osteosarcoma Metastatic |
3.3% |
| Gestational Trophoblastic Tumour |
2.8% |
| Malignant Hydatidiform Mole |
2.8% |
| Metastatic Choriocarcinoma |
2.8% |
| Osteomyelitis Bacterial |
2.8% |
| Takayasu's Arteritis |
2.8% |
| Juvenile Idiopathic Arthritis |
2.2% |
| Chemotherapy |
1.7% |
| Ill-defined Disorder |
1.7% |
| Immunosuppressant Drug Therapy |
1.7% |
|
| Rash |
8.0% |
| Sepsis |
8.0% |
| Walking Aid User |
8.0% |
| Weight Decreased |
8.0% |
| White Blood Cell Count Decreased |
8.0% |
| Acute Myeloid Leukaemia |
4.0% |
| Cholangiocarcinoma |
4.0% |
| Completed Suicide |
4.0% |
| Hepatitis B Dna Increased |
4.0% |
| High Density Lipoprotein Decreased |
4.0% |
| Hypertension |
4.0% |
| Hypothyroidism |
4.0% |
| Metastases To Peritoneum |
4.0% |
| Mucosal Inflammation |
4.0% |
| Multi-organ Failure |
4.0% |
| Nephropathy Toxic |
4.0% |
| Neurotoxicity |
4.0% |
| Neutropenic Sepsis |
4.0% |
| No Therapeutic Response |
4.0% |
| Overdose |
4.0% |
|
| Concomitant |
| Bone Marrow Conditioning Regimen |
12.7% |
| Rheumatoid Arthritis |
12.7% |
| Product Used For Unknown Indication |
11.8% |
| Acute Lymphocytic Leukaemia |
9.8% |
| Osteoporosis |
6.9% |
| Systemic Lupus Erythematosus |
6.9% |
| Immunodeficiency Common Variable |
4.9% |
| Juvenile Idiopathic Arthritis |
3.9% |
| Acute Myeloid Leukaemia |
2.9% |
| Hepatitis C |
2.9% |
| Multiple Sclerosis |
2.9% |
| Osteoporosis Prophylaxis |
2.9% |
| Psoriasis |
2.9% |
| Therapeutic Procedure |
2.9% |
| Thrombosis Prophylaxis |
2.9% |
| Drug Use For Unknown Indication |
2.0% |
| Actinic Keratosis |
2.0% |
| Cellulitis |
2.0% |
| Depression |
2.0% |
| Non-hodgkin's Lymphoma |
2.0% |
|
| Urinary Tract Infection |
10.9% |
| Stress Fracture |
8.7% |
| Vomiting |
8.7% |
| Hypersensitivity |
6.5% |
| Nausea |
6.5% |
| Thrombosis |
6.5% |
| Acute Graft Versus Host Disease |
4.3% |
| Rheumatoid Arthritis |
4.3% |
| Septic Shock |
4.3% |
| Spinal Column Stenosis |
4.3% |
| Syncope |
4.3% |
| Thrombocytopenia |
4.3% |
| Treatment Failure |
4.3% |
| Vision Blurred |
4.3% |
| Visual Impairment |
4.3% |
| Weight Decreased |
4.3% |
| Acute Generalised Exanthematous Pustulosis |
2.2% |
| Adenovirus Infection |
2.2% |
| Application Site Discolouration |
2.2% |
| Application Site Erythema |
2.2% |
|
